Lumakras (sotorasib) is a medication that’s used for metastatic non-small cell lung cancer (NSCLC). In particular, it’s used for adults who have a specific mutation called KRAS G12C in their lung cancer. Lumakras (sotorasib) is typically recommended only when first-choice treatment doesn’t work anymore. It can be a convenient option since it’s taken by mouth once a day. But, it commonly causes bothersome side effects, like stomach upset and fatigue.
Metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment
Lumakras (sotorasib) is a KRAS G12C inhibitor. KRAS is a protein in your body that sends signals to your cells to grow and divide. In certain lung cancers, a mutation (change) in KRAS called G12C leads to uncontrolled cell growth. Lumakras (sotorasib) attaches to KRAS proteins with the G12C mutation. By doing so, the medication helps block tumor growth.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Oral medication that’s taken once a day
Targeted therapy option for people with metastatic non-small cell lung cancer with a KRAS G12C mutation
Commonly causes diarrhea, nausea, muscle pain, and fatigue
Only recommended after first-choice treatment hasn’t worked
The full dose of Lumakras (sotorasib) is 960 mg once a day. In order to make the 960 mg dose, you’ll need three 320 mg tablets or eight 120 mg tablets. Take the entire dose at once each day. You don’t need to spread out the tablets throughout the day.
Swallow Lumakras (sotorasib) tablets whole. Don’t cut or crush the tablets.
If you’re having trouble swallowing Lumakras (sotorasib) tablets, you can place your dose in a glass with 4 ounces (120 mL) of room-temperature tap water. Stir or swirl the cup for about 3 minutes until the tablets break up into small pieces (the tablets won’t dissolve completely). Drink the mixture right away, and don’t chew any solid tablet pieces. Add another 4 ounces (120 mL) of water to the glass, swirl the mixture, and drink. This makes sure you’ve taken all of the medication for your dose.
If you need to take medication for heartburn, avoid medications like omeprazole (Prilosec) and famotidine (Pepcid AC) while you’re taking Lumakras (sotorasib). These medications might make Lumakras (sotorasib) not work as well. Instead, you can use an antacid like Tums. Just make sure to take Lumakras (sotorasib) 4 hours before or 10 hours after the antacid so the medications don’t interfere with each other.
If you’re starting any new medications, supplements, or herbal products, talk with your provider or pharmacist first to make sure they’re safe to take with Lumakras (sotorasib). Lumakras (sotorasib) can interact with other medications and supplements. Depending on what the specific interaction is, this can affect your risk of side effects or how well your medications work. For example, taking rosuvastatin (Crestor) with Lumakras (sotorasib) can possibly raise your risk of side effects from the cholesterol medication like joint pain or headache.
Talk with your provider or pharmacist about handling Lumakras (sotorasib) safely. Store the medication away from children and pets.
Lumakras (sotorasib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Lumakras (sotorasib) might cause damage to your liver. Because of this risk, you’ll need to get blood tests done so your healthcare provider can track how well your liver is working. You’ll typically need these blood tests before you start Lumakras (sotorasib), every 3 weeks when you first start, and then less often after that. In studies, some people experienced liver injury within the first 2 months of starting Lumakras (sotorasib). Let your healthcare team know if you notice signs of liver damage, such as pain in the right side of the stomach, yellowing of the eyes or skin, or dark or brown urine. If your provider suspects that you have liver damage, your provider might have you take a break from Lumakras (sotorasib). Once your liver test results return to normal, you might be able to restart the medication at a lower dose.
Although rare, Lumakras (sotorasib) can cause damage to the lungs, which can sometimes be life-threatening. In studies, lung problems started within the first 4 months of taking Lumakras (sotorasib). Let your healthcare team know if you experience new or worsened cough, shortness of breath, or fevers. You’ll probably need to stop the medication while your provider checks your lungs for problems.
The typical dose is 960 mg by mouth once a day, with or without food.
Lumakras (sotorasib) is available as 120 mg and 320 mg tablets. The daily dose is taken as eight 120 mg tablets or three 320 mg tablets at one time each day.
Metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment
Locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment
Locally advanced or metastatic colorectal cancer with a KRAS G12C mutation, together with Erbitux (cetuximab), after having tried certain previous cancer treatments
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
American Cancer Society. (2019). Targeted therapy safety.
American Cancer Society. (2023). If you have non-small cell lung cancer.
American Cancer Society. (2023). Targeted drug therapy for non-small cell lung cancer.
American Cancer Society. (2023). Tests for lung cancer.
American Lung Association. (2022). KRAS and lung cancer.
Amgen Inc. (n.d.). About KRAS G12C in NSCLC.
Amgen, Inc. (n.d.). About Lumakras®.
Amgen Inc. (2023). Lumakras- sotorasib tablet, coated [package insert]. DailyMed.
Nakajima, E. C., et al. (2022). FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clinical Cancer Research.
National Cancer Institute. (n.d.). Mutation.
National Cancer Institute. (n.d.). Surrogate endpoint.
National Comprehensive Cancer Network. (2023). Metastatic non-small cell lung cancer.
Skoulidis, F., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. The New England Journal of Medicine.
U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.